E-viri
Recenzirano
Odprti dostop
-
Van de Veire, Sara; Stalmans, Ingeborg; Heindryckx, Femke; Oura, Hajimu; Tijeras-Raballand, Annemilaï; Schmidt, Thomas; Loges, Sonja; Albrecht, Imke; Jonckx, Bart; Vinckier, Stefan; Van Steenkiste, Christophe; Tugues, Sònia; Rolny, Charlotte; De Mol, Maria; Dettori, Daniela; Hainaud, Patricia; Coenegrachts, Lieve; Contreres, Jean-Olivier; Van Bergen, Tine; Cuervo, Henar; Xiao, Wei-Hong; Le Henaff, Carole; Buysschaert, Ian; Masouleh, Behzad Kharabi; Geerts, Anja; Schomber, Tibor; Bonnin, Philippe; Lambert, Vincent; Haustraete, Jurgen; Zacchigna, Serena; Rakic, Jean-Marie; Jiménez, Wladimiro; Noël, Agnes; Giacca, Mauro; Colle, Isabelle; Foidart, Jean-Michel; Tobelem, Gerard; Morales-Ruiz, Manuel; Vilar, José; Maxwell, Patrick; Vinores, Stanley A.; Carmeliet, Geert; Dewerchin, Mieke; Claesson-Welsh, Lena; Dupuy, Evelyne; Van Vlierberghe, Hans; Christofori, Gerhard; Mazzone, Massimiliano; Detmar, Michael; Collen, Désiré; Carmeliet, Peter
Cell, 2010, Letnik: 141, Številka: 1Journal Article, Web Resource
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies. ► PlGF inhibition phenocopies genetic deficiency in tumor models and ocular angiogenesis ► PlGF inhibition blocks vessel abnormalization rather than density in certain tumors ► Anti-mouse and anti-human PlGF antibodies are specific and efficacious ► Anti-PlGF treatment lacks efficacy in some cancer models
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.